A multi-component fluorescence composite strategy for constructing a mesh coating pattern: Design, synthesis, cell imaging, and bioactivity study of a visual antitumor fluorescent complex

A novel visualized anti-tumor complex was designed to accomplish the targeting and visualization of anti-tumor drugs, thereby reducing adverse drug reactions and achieving precision medicine. One-pot fluorescent complexes were created using isorhamnetin, nido -carborane, and rhodamine B as raw materials. By embedding these complexes in four medicinal acrylic resins, which are high molecular-weight polymers prepared by polymerization reactions of acrylic acid or methacrylic acid and their ester monomers, a series of fluorescent anti-tumor complexes Eudragit ® L 100-55@isorhamnetin/ nido -carborane/rhodamine B ( L-ICR ), Eudragit ® E PO@isorhamnetin/ nido -carborane/rhodamine B ( E-ICR ), Eudragit ® RS 100@isorhamnetin/ nido -carborane/rhodamine B ( S-ICR ), and Eudragit ® RL 100@isorhamnetin/ nido -carborane/rhodamine B ( R-ICR ) were created, which enhanced the bioavailability and stability of isorhamnetin and nido -carborane and made it possible to see the specific locations where medications were targeted. L-ICR was then screened using the cell proliferation toxicity test (CCK8), which had a greater anti-tumor effect. As the concentration of L-ICR reached 24 µg/mL, the inhibition rate of HeLa cells and PC3 cells was 67.66% and 48.25%, respectively. Using transmission electron microscopy (TEM), it was observed that the internal microstructure of L-ICR was tightly wrapped in an acrylic resin network. According to in vitro tumor cell imaging experiments, L-ICR exhibited good biocompatibility and selectivity, as most tumor cells were successfully entered into the nucleus. The complex in this study was a good fluorescent anti-tumor complex, with great imaging and targeting effect, and anti-tumor ability, which provided a new idea for the further development of anti-tumor drugs in the future.